FORM 4

(Print or Tuno Posnonsos

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

SEC 1474 (9-02)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address MONAHAN JOHN	2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
3150 ALMADEN	(First) EXPRESSWAY		3. Date of Earliest Transaction (Month/Day/Year) 10/08/2018							ther (specify belo	ow)
SAN JOSE, CA 95	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security 2. Transaction (Instr. 3) Date (Month/Day/Year)			(Instr. 8)	tion	(A) or Disposed of (D)			Owned Following Reported Transaction(s)	Ownership of India	Beneficial	
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	or Indirect (D) or Indirect (I) (Instr. 4)	-
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly											

Persons who respond to the collection of information

contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	er	6. Date Exer	rcisable and	7. Title and	l	8. Price of	9. Number of	10.	11. Nature
	Conversion		Execution Date, if					Expiration I		Amount of				Ownership	
-		(Month/Day/Year)		Code		Derivativ		(Month/Day	· · · · · · · · · · · · · · · · · · ·	Underlying		-			Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securitie				Securities		· · · · ·	-	Derivative	-
	Derivative					Acquired	1			(Instr. 3 and	d 4)			-	(Instr. 4)
	Security					(A) or Disposed of						Direct (D) or Indirect			
						(D)					Transaction(s)				
						(Instr. 3,	4,							(Instr. 4)	
						and 5)							, í		
											Amount	1			
								Date	Expiration		or				
								Exercisable	1	Title	Number				
									Date		of				
				Code	V	(A)	(D)				Shares				
Employee															
Stock										a					
Option	\$ 5.29	10/08/2018		А		45,000		<u>(2)</u>	10/08/2028	Common Stock	45,000	\$ 0	45,000	D	
(Right to						,				Stock	,		,		
$(\text{Buy}) \frac{(1)}{(1)}$															
Buy)															

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
MONAHAN JOHN J 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE, CA 95118	Х							

Signatures

/s/ John Monahan	10/09/2018	
Signature of Reporting Person	Date	

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2010 Share Incentive Plan.

(2) The options vest and become exercisable in twelve (12) equal monthly installments beginning October 31, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.